1National Committee for Clinical Laboratory Standards.2002.Reference method for broth dilution antifungal susceptibility testing of filamentous fungi.Approved standard M38-A [ J ].National Committee for Clinical Laboratory Standards,Wayne,Pa. 被引量：1
2Pfaller MA,Boyken L,Hollis R J,et al.Susceptibilities of clinical Isolates of Candida Species,Cryptococcus neoformans,and Aspergillus species to itraconazole:global survey of 9,359 isolates tested by Clinical and Laboratory Standards Institute broth microdilution methods [ J ].J of Clin Microbiol,2005,43:3807-38100. 被引量：1
5Yao Z, Liao W, Chen R. Management of cryptococcosis in non HIV-related patients. Med Mycol, 2005,43:245. 被引量：1
6Slade E, Tamber PS, Vincent JL. The Surviving Sepsis Campaign: raising awareness to reduce mortality. Crit Care, 2003, 7:. 被引量：1
7Yang CJ, Hwang JJ, Wang TH, et al. Clinical and radiographic presentations of pulmonary eryptococcosis in immunocompetent patients. Scand J Infect Dis, 2006,38:788. 被引量：1
8Salyer WR, Salyer DC, Baker RD. Primary complex of Cryptococcus and pulmonary lymph nodes. J Infect Dis, 1974,130:7. 被引量：1
9Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated eryptocoecal meningitis. The NIAID Mycoses Study Group and the AIDS Clinieat Trials Group. N Engl J Med, 1992, 326 : 83. 被引量：1
10Berry AJ, Rinaldi MG, Graybill JR. Use of high-dose flueonazole as salvage therapy for eryptococcal meningitis in patients with AIDS. Antimierob Agents Chemother, 1992,36:690. 被引量：1
